Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
GAITHERSBURG, Md., March 16, 2017 -- OpGen, Inc. (NASDAQ:OPGN) today announced that it will report its 2016 fourth quarter and year end financial results after close of market Thursday, March 23, 2017. OpGen’s management team will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the company’s financial results and recent developments.
Dial-in Information
U.S. Dial-In Number: 844-420-8185
International Dial-In Number: 216-562-0481
Conference ID: 87850606
Replay Dial-In Information
U.S. Dial-In Number: 855-859-2056
International Dial-In Number: 404-537-3406
Conference ID: 87850606
The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the company’s website at http://ir.opgen.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website for 90 days.
About OpGen
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn.
Company Contact: Michael Farmer Director, Marketing (240) 813-1284 [email protected] [email protected] Investor and Media Contact: MacDougall Biomedical Communications Cammy Duong 781-235-3060 [email protected]
